CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab
Journal of the National Comprehensive Cancer Network · 31.03.2026 · 24 (3.5)
DOI: 10.6004/jnccn.2025.7438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, erschienen am 31.03.2026. Verfasst von Truman Koh und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1University of Texas Southwestern Medical Center, Dallas, TX.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- 1University of Texas Southwestern Medical Center, Dallas, TX.
Zitieren
APA
Koh, T., Zou, K., & Awan, F. (2026). CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab. Journal of the National Comprehensive Cancer Network, 24(3.5). https://doi.org/10.6004/jnccn.2025.7438
Vancouver
Koh T, Zou K, Awan F. CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab. Journal of the National Comprehensive Cancer Network. 2026;24(3.5). doi:10.6004/jnccn.2025.7438
BibTeX
@article{Koh2026,
author = {Koh, Truman and Zou, Ken and Awan, Farrukh},
title = {CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {3.5},
doi = {10.6004/jnccn.2025.7438}
}
EUVIMED